Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study

Ruth Van Daele, Joost Wauters, Erwin Dreesen, Jerina Boelens, Eric Nulens, Piet Lormans, Lore Vanderbeke, Cato Jacobs, Bart Rijnders, Paul E. Verweij, Roger J. Brüggemann, Isabel Spriet

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

1 Citaat (Scopus)

Samenvatting

Background: Data on posaconazole in the critically ill are scarce. In the POSA-FLU study, we examined the prevention of influenza-associated pulmonary aspergillosis with posaconazole in this population. Methods: In this observational sub-study, we performed a pharmacokinetic analysis, including protein binding and target attainment (TA). Blood samples were collected over a 24 h-dosing interval on both an early (Day 2 or 3) and a later (≥Day 4) treatment day. Results: Target attainment was shown for AUC0-24 and Cmin prophylaxis but not for Cmin treatment. Moreover, a saturable protein binding with a significant, positive relationship between albumin concentrations and the maximum binding capacity was observed. Conclusions: Our analysis indicates that posaconazole may be a suitable drug to further investigate for prophylaxis, as TA for prophylaxis was reached. Exposure targets for treatment were insufficiently attained in this population.

Originele taal-2Engels
Pagina's (van-tot)656-660
Aantal pagina's5
TijdschriftMycoses
Volume65
Nummer van het tijdschrift6
DOI's
StatusGepubliceerd - jun. 2022
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study'. Samen vormen ze een unieke vingerafdruk.

Citeer dit